retatrutide phase 2 trial type 2 diabetes results 2024 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first 3 for treatment of Phase 2 trial results demonstrate

Patients who maintained their chosen injection day lost significantly more weight than those with irregular schedules, regardless of whether they chose morning or evening

Tell your doctor immediately if you notice any change in your vision particularly sudden, painless visual loss or a new visual field defect

If you're using semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, or another medically supervised weight loss tool, your macros should reflect your actual situation

& Evans, C

Net Weight: 125g

Practical strategies that trial participants and clinicians report as effective: Dietary modifications work best